Open AccessA cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)
Author(s) -
Jordi Castellsagué,
Josephina G. Kuiper,
Anton Pottegård,
Ingegärd Anveden Berglind,
Daniel Dedman,
Lia Gutiérrez,
Brian Calingaert,
Myrthe P. P. van HerkSukel,
Jesper Hallas,
Anders Sundström,
Arlene M. Gallagher,
James A. Kaye,
C de Miguel Pardo,
Kenneth J. Rothman,
Susana PerezGutthann
Publication year - 2018
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s146442
Subject(s) - pimecrolimus , medicine , tacrolimus , skin cancer , incidence (geometry) , population , dermatology , lymphoma , cohort , cohort study , cancer registry , calcineurin , cancer , transplantation , environmental health , physics , optics
There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children.